期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 59, 期 4, 页码 1545-1555出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.5b01493
关键词
-
资金
- Deutsche Forschungsgemeinschaft [HDAC6, Ju295/10-2, CRU201, HDAC8, Ju295/13-1, Si846/13-1, OE542/2-1, WI1461/4-1, Ju295/9-2, SPP1463]
- Centre National de la Recherche Scientifique (CNRS)
- Institute National de la Sante et de la Recherche Medicale (INSERM)
- Universite de Strasbourg
- French Infrastructure for Integrated Structural Biology (FRISBI) [ANR-10-INSB-05-01]
- European Strategy Forum on Research Infrastructures (ESFRI)
Histone deacetylase 6 (HDAC6) catalyzes the removal of an acetyl group from lysine residues of several nonhistone proteins. Here we report the preparation of thiazole-, oxazole-, and oxadiazole-containing biarylhydroxamic acids by a short synthetic procedure. We identified them as selective HDAC6 inhibitors by investigating the inhibition of B recombinant HDAC enzymes and the protein acetylation in cells by Western blotting (tubulin vs histone acetylation). The most active compounds exhibited nanomolar potency and high selectivity for HDAC6. For example, an oxazole hydroxamate inhibits HDAC6 with an IC50 of 59 nM and has a selectivity index of >200 against HDAC1 and HDAC8. This is the first report showing that the nature of a heterocycle directly connected to a zinc binding group (ZBG) can be used to modulate subtype selectivity and potency for HDAC6 inhibitors to such an extent. We rationalize the high potency and selectivity of the oxazoles by molecular modeling and docking.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据